Companies › PersonGen BioTherapeutics (Suzhou)
3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PA3-17 injection anti-CD7 CAR-T cell therapy | CD7 | Phase 2 | CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma | Oct 2027 |
| LV009 Injection Anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | Non-Hodgkin Lymphoma | Dec 2026 |
| TAA06 Injection B7-H3-targeted CAR-T cell therapy | B7H3 | Phase 1 | B7-H3-positive Relapsed/ Refractory Neuroblastoma | Feb 2039 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07284927 | LV009 Injection | Phase 1 | Non-Hodgkin Lymphoma | Oncology | Dec 2026 |
| NCT07188610 | PA3-17 injection | Phase 2 | CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma | Oncology | Oct 2027 |
| NCT05562024 | TAA06 Injection | Phase 1 | B7-H3-positive Relapsed/ Refractory Neuroblastoma | Oncology | Feb 2039 |
Hebei Senlang Biotechnology Beijing Yongtai Ruike Biotechnology Company Allotera Therapeutics Juventas Cell Therapy Jiangsu Topcel-KH Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.